New preliminary research presented at the American Heart Association’s Scientific Sessions in Chicago indicates that caffeinated energy drinks and stimulant supplements appear far more often in FDA adverse‑event reports of serious heart problems than other food and supplement categories. The association is strongest for cardiac arrest and heart attacks among adults aged 18 to 34, a demographic typically considered low‑risk for such events.
Key Findings from FDA Data
Researchers examined 28,345 voluntary reports submitted to an FDA safety database covering the period 2017‑2025. Of these, 854 reports mentioned products containing caffeine or other stimulants, while the remaining 27,491 involved items without such ingredients. Compared with non‑caffeinated products, the analysis found:
- Cardiac arrest was reported roughly 11 times more frequently.
- Heart attacks appeared about 4.5 times more often.
- Ventricular arrhythmias or palpitations were four times as common.
- Elevated heart rate was nearly three times more likely.
- Chest pain occurred 2.71 times more often.
- Fainting was reported about twice as often.
Approximately 45 % of the caffeine‑related cardiovascular reports involved individuals aged 18‑34, and similar patterns were observed for both men and women.
Industry Context and Regulatory Landscape
Sales of caffeinated energy drinks have more than doubled over the past decade, surpassing $20 billion in 2024. While a standard cup of black coffee contains up to 400 mg of caffeine per day—generally regarded as safe for most adults—many energy drinks contain up to three times that amount per fluid ounce, and some pre‑workout supplements exceed it by more than twelve times. Because the U.S. Food and Drug Administration classifies these products as foods or dietary supplements rather than medicines, they are not subject to the same pre‑market safety testing required for pharmaceuticals.
Healthcare professionals have documented cases of arrhythmias and sudden cardiac death in young adults who consumed these products, often without any known heart‑disease risk factors. The rapid rise in consumption, combined with the high caffeine concentrations, has prompted calls for more systematic safety monitoring.
Expert Commentary and Study Limitations
“These products are marketed as everyday pick‑me‑ups and sit next to soda and bottled water, so most people assume they carry no real risk,” said study author Sai Samayamanthula, a fourth‑year medical student at the University of Virginia School of Medicine. “Occasional use probably poses a small risk, but regular consumption can quickly exceed recommended caffeine limits, raising the potential for cardiovascular harm.”
Gregory M. Marcus, MD, chair of the 2026 AHA scientific statement on caffeine and cardiovascular disease, cautioned that the findings do not prove causation. “Biological mechanisms could link high caffeine doses to heart events, but other factors may have influenced these results. More research is needed to determine whether the products are truly responsible.”
The study’s authors emphasized several constraints: the analysis relies on voluntarily submitted reports, which may not represent all users or all adverse outcomes; the data cannot establish direct cause‑and‑effect relationships; and the product categories were grouped by ingredient type rather than brand, limiting conclusions about specific products.
Given these limitations, the researchers recommend that clinicians ask younger patients presenting with palpitations, chest pain, or fainting about recent or regular intake of caffeinated energy drinks or stimulant supplements. Systematic post‑market surveillance and peer‑reviewed research are needed to clarify the true risk profile of these high‑caffeine products.
Mitchell Landsberg is a Senior Technology Correspondent at News Raise. He covers consumer electronics, artificial intelligence, software developments, and digital privacy trends.
